Testing for COVID-19: Increasing testing supply

On this page

What Canada is doing

Canada is mobilizing industry and providing support for research, market approval, manufacturing and access to medical supplies. We're working proactively with companies that are developing new and innovative testing technologies. We're also engaging with international regulators to share knowledge about new developments related to testing.

Increasing testing options

Health Canada reviews testing devices to assess their safety, effectiveness and quality before they're authorized for sale in Canada. For a test to be authorized by Health Canada, it must be submitted for review by the manufacturer. To date, Health Canada has authorized over 50 different COVID-19 tests. We also continue to expedite the review of COVID-19 tests, including new testing options.

Health Canada is currently prioritizing the review of:

Health Canada has received a number of antigen test applications that are under priority review. Antigen tests detect specific proteins on the surface of the virus and provide rapid results.

A small number of saliva tests have been submitted to Health Canada and are under priority review. Health Canada hasn't authorized any tests for use with saliva at this time.

Health Canada will expedite the review of any new testing technologies submitted by manufacturers, including at-home test kits (also known as "self-testing"). For at-home test kits, the manufacturer must provide data to show the test is safe and effective for Canadians to use without health care professional supervision.

In all cases, companies must provide evidence that the test is accurate and reliable before Health Canada will authorize it. Health Canada has provided guidance to manufacturers on the authorization requirements for different types of tests such as antibody tests and antigen tests.

Securing rapid tests

Public Services and Procurement Canada has purchased rapid tests on behalf of and at the direction of the Public Health Agency of Canada. This purchase ensures that the federal government can increase testing capacity with authorized, proven and effective technologies. Explore COVID-19 rapid test purchase agreements.

Rapid tests distributed in Canada

The Government of Canada has purchased over 59 million units of the following rapid tests: Abbott Panbio, Abbott ID Now, BD Veritor, Quidel Sofia and BTNX.

The tables below show the number of COVID-19 rapid tests that have been shipped in provinces and territories as of October 08, 2021 (deployment data as of October 07, 2021). The data for “tests deployed” show the quantities of rapid tests that have been distributed to their final point-of-care setting where they will be administered to patients. The data for “tests used” depict how many of those rapid tests have been administered. 

There is a delay in the reporting on the deployment of rapid tests. This is due to the time when tests are:

The numbers listed are updated once a week.

Canada
Distribution of tests in Canada
Product name Tests received Tests shipped to PTs and Federal Allocation Tests deployedFootnote * Tests used (as reported)Footnote ** Strategic Supply
Abbott ID Now 6,611,544 4,510,872 1,803,307 840,231 1,848,096
Abbott Panbio 37,727,900 31,521,138 30,050,520 9,302,758 253,950
BD Veritor 11,599,980 7,008,000 3,942,419 603,621 2,036,760
Quidel Sofia 850,000 90,600 0 1,056 759,400
BTNX 2,249,350 0 0 0 249,350
Total 59,038,774 43,130,610 35,796,246 10,747,666 5,147,556
Footnote *

The test deployed information show the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used.

Return to footnote * referrer

Footnote **

The tests used information shows data that has been reported to Health Canada to date.

Return to footnote ** referrer

Newfoundland and Labrador
Distribution of tests for Newfoundland and Labrador
Product name Tests received Tests deployedFootnote * Tests used (as reported)Footnote **
Abbott ID Now 85,432 86,208 9,177
Abbott Panbio 304,200 304,375 15,258
BD Veritor 0 0 0
BTNX 0 0 0
Total 389,632 390,583 24,435
Footnote *

The test deployed information show the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used.

Return to footnote * referrer

Footnote **

The tests used information shows data that has been reported to Health Canada to date.

Return to footnote ** referrer

Prince Edward Island
Distribution of tests for Prince Edward Island
Product name Tests received Tests deployedFootnote * Tests used (as reported)Footnote **
Abbott ID Now 365,688 no information provided 188,567
Abbott Panbio 106,000 no information provided no information provided
BD Veritor 0 0 0
BTNX 40,000 0 0
Total 511,688 no information provided 188,657
Footnote *

The test deployed information show the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used.

Return to footnote * referrer

Footnote **

The tests used information shows data that has been reported to Health Canada to date.

Return to footnote ** referrer

Nova Scotia
Distribution of tests for Nova Scotia
Product name Tests received Tests deployedFootnote * Tests used (as reported)Footnote **
Abbott ID Now 106,512 1,491 1,491
Abbott Panbio 1,421,125 749,214 469,264
BD Veritor 540,360 63,439 63,439
BTNX 0 0 0
Total 2,067,977 814,144 534,194
Footnote *

The test deployed information show the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used.

Return to footnote * referrer

Footnote **

The tests used information shows data that has been reported to Health Canada to date.

Return to footnote ** referrer

New Brunswick
Distribution of tests for New Brunswick
Product name Tests received Tests deployedFootnote * Tests used (as reported)Footnote **
Abbott ID Now 78,912 12,736 328
Abbott Panbio 1,471,200 520,075 62,558
BD Veritor 0 0 0
BTNX 250,000 0 0
Total 1,800,112 532,811 62,886
Footnote *

The test deployed information show the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used.

Return to footnote * referrer

Footnote **

The tests used information shows data that has been reported to Health Canada to date.

Return to footnote ** referrer

Quebec
Distribution of tests for Quebec
Product name Tests received Tests deployedFootnote * Tests used (as reported)Footnote **
Abbott ID Now 822,816 751,176 239,909
Abbott Panbio 3,563,750 2,908,144 9,954
BD Veritor 911,280 604,560 35,419
BTNX 0 0 0
Total 5,297,646 4,263,880 285,282
Footnote *

The test deployed information show the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used.

Return to footnote * referrer

Footnote **

The tests used information shows data that has been reported to Health Canada to date.

Return to footnote ** referrer

Ontario
Distribution of tests for Ontario
Product name Tests received Tests deployedFootnote * Tests used (as reported)Footnote **
Abbott ID Now 1,218,144 473,954 82,298
Abbott Panbio 17,179,738 25,471,720 7,011,292
BD Veritor 4,033,740 1,063,865 190,857
Quidel Sofia 73,200 0 0
BTNX 750,000 0 0
Total 23,254,822 27,009,539 7,284,447
Footnote *

The test deployed information show the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used and may also include tests purchased by the province.

Return to footnote * referrer

Footnote **

The tests used information shows data that has been reported to Health Canada to date and may also include tests purchased by the province.

Return to footnote ** referrer

Manitoba
Distribution of tests for Manitoba
Product name Tests received Tests deployedFootnote * Tests used (as reported)Footnote **
Abbott ID Now 176,448 21,024 no information provided
Abbott Panbio 787,825 407,475 no information provided
BD Veritor 695,010 11,520 no information provided
BTNX 0 0 no information provided
Total 1,659,283 440,019 no information provided
Footnote *

The test deployed information show the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used and may also include tests purchased by the province.

Return to footnote * referrer

Footnote **

The tests used information shows data that has been reported to Health Canada to date and may also include tests purchased by the province.

Return to footnote ** referrer

Saskatchewan
Distribution of tests for Saskatchewan
Product name Tests received Tests deployedFootnote * Tests used (as reported)Footnote **
Abbott ID Now 348,446 150,528 125,625
Abbott Panbio 2,854,875 1,708,400 232,114
BD Veritor 1,351,770 50,790 0
BTNX 500,650 0 0
Total 5,055,741 1,909,718 357,739
Footnote *

The test deployed information show the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used.

Return to footnote * referrer

Footnote **

The tests used information shows data that has been reported to Health Canada to date.

Return to footnote ** referrer

Alberta
Distribution of tests for Alberta
Product name Tests received Tests deployedFootnote * Tests used (as reported)Footnote **
Abbott ID Now 537,912 251,974 154,878
Abbott Panbio 3,599,522 3,480,412 860,363
BD Veritor 936,720 985,058 201,276
BTNX 459,350 0 0
Total 5,533,504 4,717,444 1,216,517
Footnote *

The test deployed information show the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used.

Return to footnote * referrer

Footnote **

The tests used information shows data that has been reported to Health Canada to date.

Return to footnote ** referrer

British Columbia
Distribution of tests for British Columbia
Product name Tests received Tests deployedFootnote * Tests used (as reported)Footnote **
Abbott ID Now 626,976 79,080 16,801
Abbott Panbio 2,130,850 766,051 142,219
BD Veritor 389,880 51,090 27,147
BTNX 0 0 0
Total 3,147,706 896,221 186,167
Footnote *

The test deployed information show the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used.

Return to footnote * referrer

Footnote **

The tests used information shows data that has been reported to Health Canada to date.

Return to footnote ** referrer

Yukon
Distribution of tests for Yukon
Product name Tests received Tests deployedFootnote * Tests used (as reported)Footnote **
Abbott ID Now 15,720 no information provided no information provided
Abbott Panbio 13,600 no information provided no information provided
BD Veritor 0 0 0
BTNX 0 0 0
Total 29,320 0 0
Footnote *

The test deployed information show the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used.

Return to footnote * referrer

Footnote **

The tests used information shows data that has been reported to Health Canada to date.

Return to footnote ** referrer

Northwest Territories
Distribution of tests for Northwest Territories
Product name Tests received Tests deployedFootnote * Tests used (as reported)Footnote **
Abbott ID Now 63,960 4,944 4,188
Abbott Panbio 34,800 3,825 136
BD Veritor 0 0 0
BTNX 0 0 0
Total 98,760 8,769 4,324
Footnote *

The test deployed information show the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used.

Return to footnote * referrer

Footnote **

The tests used information shows data that has been reported to Health Canada to date.

Return to footnote ** referrer

Nunavut
Distribution of tests for Nunavut
Product name Tests received Tests deployedFootnote * Tests used (as reported)Footnote **
Abbott ID Now 25,416 5,424 no information provided
Abbott Panbio 25,400 14,400 no information provided
BD Veritor 0 0 no information provided
BTNX 0 0 no information provided
Total 50,816 19,824 no information provided
Footnote *

The test deployed information show the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used.

Return to footnote * referrer

Footnote **

The tests used information shows data that has been reported to Health Canada to date.

Return to footnote ** referrer

Federal allocation
Distribution of tests for Federal OperationsFootnote *
Product name Tests received Tests deployedFootnote ** Tests used (as reported)Footnote ***
Abbott ID Now 280,136 156,408 16,879
Abbott Panbio 434,350 253,900 89,945
BD Veritor 11,600 0 0
Quidel Sofia 8,400 0 1,056
Total 734,486 410,308 107,880
Footnote *

The federal operations numbers include tests distributed to federal government departments such as: Department of National Defence (DND), Correctional Services Canada (CSC), the Public Health Agency of Canada (PHAC), as well as Northern, remote and Indigenous communities.

Return to footnote * referrer

Footnote **

The test deployed information show the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used.

Return to footnote ** referrer

Footnote ***

The tests used information shows data that has been reported to Health Canada to date.

Return to footnote *** referrer

Direct to organizations for workplace screeningFootnote *
Product name Tests available Tests deployedFootnote ** Tests used (as reported)Footnote ***
Abbott ID Now 24,984 0 0
Abbott Panbio 2,826,900 2,727,900 409,655
BD Veritor 995,080 1,804,650 85,483
Quidel Sofia 9,000 0 0
Total 3,855,964 4,532,550 495,138
Footnote *

Federal distribution numbers include tests shipped to businesses, non-profit organizations, crown corporations, and distribution partners such as pharmacies and the Canadian Red Cross.

Return to footnote * referrer

Footnote **

The test deployed information show the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used.

Return to footnote ** referrer

Footnote ***

The tests used information shows data that has been reported to Health Canada to date.

Return to footnote *** referrer

Supporting provincial and territorial COVID-19 testing capacity

The federal government is providing $4.28 billion to the provinces and territories. This money is to help them conduct testing, perform contact tracing and share public health data that will help fight the pandemic. The goal is to ensure they have the capacity to test up to 200,000 people each day, nationwide.

Canada is also providing funding and support to improve and modernize data management across Canada. This support is to help all levels of government coordinate their efforts to contain the virus.

The table below shows the current capacity for each province and territory compared to the capacity target agreed to under the Safe Restart Agreement.

The national capacity target of about 200,000 tests each day is based on modelling. This modelling exercise indicates this capacity is enough to meet the expected demand for testing.

Provincial and territorial COVID-19 testing capacity

Testing capacity reported as of September 30, 2021.

Please consult the Coronavirus disease 2019 (COVID-19): Epidemiology update for daily and weekly updates on the average number of people tested.

In circumstances where capacity was not reported, the previous week's capacity was indicated (see *).

Newfoundland and Labrador: Target 2,500 - 3,000
COVID-19 testing capacity for Newfoundland and Labrador (Target 2,500 - 3,000Footnote***)
Date Projected daily maximum testing capacity
2020-09-03 1,450
2020-09-10 1,450
2020-09-17 1,450
2020-09-24 1,450
2020-10-01 1,450
2020-10-08 1,450
2020-10-15 1,450
2020-10-22 1,450
2020-10-29 1,450
2020-11-03 1,450
2020-11-10 1,450
2020-11-17 1,450
2020-11-24 1,450
2020-12-01 1,450
2020-12-08 1,450
2020-12-15 1,450
2020-12-22 1,450
2020-12-29 1,450
2021-01-05 1,450
2021-01-12 1,450
2021-01-19 1,450
2021-01-26 1,450
2021-02-02 1,450
2021-02-09 1,700
2021-02-16 1,700Footnote *
2021-02-23 1,700
2021-03-02 1,700
2021-03-09 1,700
2021-03-16 1,700
2021-03-23 2,100
2021-03-29 2,100
2021-04-06 2,100
2021-04-12 2,500
2021-04-19 2,500
2021-04-26 2,500
2021-05-03 2,700
2021-05-10 2,700
2021-05-17 2,700
2021-05-24 2,700
2021-05-31 2,700
2021-06-30 2,700
2021-07-31 2,700
2021-08-31 2,700
2021-09-30 2,700
Footnote ***

Target updated October 6 at the request of Newfoundland and Labrador

Return to footnote*** referrer

Prince Edward Island: Target 835
COVID-19 testing capacity for Prince Edward Island (Target 835)
Date Projected daily maximum testing capacity
2020-09-03 350
2020-09-10 430
2020-09-17 350
2020-09-24 350
2020-10-01 400
2020-10-08 400
2020-10-15 400 (800Footnote**)
2020-10-22 400 (800Footnote**)
2020-10-29 400 (800Footnote**)
2020-11-03 400 (800Footnote**)
2020-11-10 400 (800Footnote**)
2020-11-17 400 (800Footnote**)
2020-11-24 400 (800Footnote**)
2020-12-01 400 (800Footnote**)
2020-12-08 400Footnote* (800Footnote**)
2020-12-15 400 (800Footnote**)
2020-12-22 400
2020-12-29 400
2021-01-05 600
2021-01-12 600
2021-01-19 600
2021-01-26 600
2021-02-02 700
2021-02-09 850
2021-02-16 850
2021-02-23 850
2021-03-02 850
2021-03-09 850
2021-03-16 850
2021-03-23 850
2021-03-29 850
2021-04-06 850
2021-04-12 850
2021-04-19 850
2021-04-26 850
2021-05-03 850
2021-05-10 850
2021-05-17 850
2021-05-24 850
2021-05-31 850
2021-06-30 850
2021-07-31 850
2021-08-31 850
2021-09-30 850
Footnote **

Revised to include the surge testing capacity available on a temporary basis.

Return to footnote** referrer

Nova Scotia: Target 2,500
COVID-19 testing capacity for Nova Scotia (Target 2,500)
Date Projected daily maximum testing capacity
2020-09-03 1,500
2020-09-10 1,500
2020-09-17 1,500
2020-09-24 1,500
2020-10-01 1,500
2020-10-08 1,500
2020-10-15 1,500
2020-10-22 1,500
2020-10-29 1,500
2020-11-03 1,500
2020-11-10 1,500
2020-11-17 1,500
2020-11-24 2,500
2020-12-01 2,500
2020-12-08 2,500
2020-12-15 2,500
2020-12-22 2,500
2020-12-29 2,500
2021-01-05 2,500
2021-01-12 2,500
2021-01-19 2,500
2021-01-26 2,500
2021-02-02 2,500
2021-02-09 2,500
2021-02-16 2,500
2021-02-23 2,500
2021-03-02 2,500
2021-03-09 2,500
2021-03-16 2,500
2021-03-23 2,500
2021-03-29 2,500
2021-04-06 2,500
2021-04-12 2,500
2021-04-19 2,500
2021-04-26 2,500
2021-05-03 10,000
2021-05-10 10,000
2021-05-17 10,000
2021-05-24 10,000
2021-05-31 10,000
2021-06-30 10,000
2021-07-31 10,000
2021-08-31 10,000
2021-09-30 10,000
New Brunswick: Target 2,500 - 3,000
COVID-19 testing capacity for New Brunswick (Target 2,500 - 3,000)
Date Projected daily maximum testing capacity
2020-09-03 1,500
2020-09-10 1,500
2020-09-17 1,500
2020-09-24 1,500
2020-10-01 1,500
2020-10-08 1,500
2020-10-15 1,500
2020-10-22 1,500
2020-10-29 2,000
2020-11-03 2,000
2020-11-10 2,000
2020-11-17 2,000
2020-11-24 2,000Footnote*
2020-12-01 2,000
2020-12-08 2,000Footnote*
2020-12-15 2,500
2020-12-22 2,500
2020-12-29 2,500
2021-01-05 2,500
2021-01-12 2,000
2021-01-19 2,000
2021-01-26 2,000
2021-02-02 2,000
2021-02-09 3,000
2021-02-16 3,000
2021-02-23 3,000
2021-03-02 3,000
2021-03-09 3,000
2021-03-16 3,000
2021-03-23 3,000
2021-03-29 3,000
2021-04-06 3,000
2021-04-12 3,000
2021-04-19 3,000
2021-04-26 3,000
2021-05-03 3,000
2021-05-10 3,000
2021-05-17 3,000
2021-05-24 3,000
2021-05-31 3,000
2021-06-30 3,000
2021-07-31 3,000
2021-08-31 3,000
2021-09-30 3,000
Quebec: Target 35,000
COVID-19 testing capacity for Quebec (Target 35,000)
Date Projected daily maximum testing capacity
2020-09-03 20,000
2020-09-10 20,000
2020-09-17 20,000
2020-09-24 20,000
2020-10-01 20,000
2020-10-08 20,000
2020-10-15 20,000
2020-10-22 20,000
2020-10-29 20,000
2020-11-03 20,000
2020-11-10 20,000
2020-11-17 20,000
2020-11-24 20,000
2020-12-01 20,000
2020-12-08 35,199
2020-12-15 37,142
2020-12-22 38,846
2020-12-29 40,196
2021-01-05 37,972
2021-01-12 39,127
2021-01-19 36,929
2021-01-26 40,084
2021-02-02 40,977
2021-02-09 42,386
2021-02-16 39,497
2021-02-23 43,987
2021-03-02 41,386
2021-03-09 42,758
2021-03-16 42,427
2021-03-23 43,382
2021-03-29 44,037
2021-04-06 46,392
2021-04-12 48,221
2021-04-19 47,959
2021-04-26 47,659
2021-05-03 47,771
2021-05-10 48,098
2021-05-17 48,471
2021-05-24 46,104
2021-05-31 46,338
2021-06-30 46,048
2021-07-31 46,048
2021-08-31 47,653
2021-09-30 47,653
Ontario: Target 78,000
COVID-19 testing capacity for Ontario (Target 78,000)
Date Projected daily maximum testing capacity
2020-09-03 35,108
2020-09-10 39,690
2020-09-17 42,434
2020-09-24 42,816
2020-10-01 42,942
2020-10-08 50,692
2020-10-15 51,397
2020-10-22 64,340
2020-10-29 67,094
2020-11-03 71,564
2020-11-10 78,964
2020-11-17 80,856
2020-11-24 81,630
2020-12-01 81,630
2020-12-08 74,008
2020-12-15 77,333
2020-12-22 77,333
2020-12-29 77,581
2021-01-05 79,821
2021-01-12 120,608
2021-01-19 120,608
2021-01-26 120,608
2021-02-02 116,000
2021-02-09 116,000
2021-02-16 116,000
2021-02-23 116,000
2021-03-02 116,000
2021-03-09 117,800
2021-03-16 118,400
2021-03-23 118,400
2021-03-29 118,400
2021-04-06 120,200
2021-04-12 120,200
2021-04-19 120,200
2021-04-26 120,200
2021-05-03 120,200
2021-05-10 124,700
2021-05-17 124,700
2021-05-24 124,700
2021-05-31 124,700
2021-06-30 124,700
2021-07-31 124,700
2021-08-31 124,700
2021-09-30 124,700
Manitoba: Target 3,000
COVID-19 testing capacity for Manitoba (Target 3,000)
Date Projected daily maximum testing capacity
2020-09-03 3,000
2020-09-10 3,000
2020-09-17 3,000
2020-09-24 3,000
2020-10-01 3,000
2020-10-08 3,000
2020-10-15 3,000
2020-10-22 3,000
2020-10-29 3,000
2020-11-03 3,000
2020-11-10 3,000
2020-11-17 3,000
2020-11-24 3,000Footnote*
2020-12-01 2,841
2020-12-08 2,841Footnote*
2020-12-15 2,841Footnote*
2020-12-22 3,500
2020-12-29 3,500
2021-01-05 3,500
2021-01-12 3,500
2021-01-19 3,500
2021-01-26 3,500
2021-02-02 3,500
2021-02-09 3,500Footnote*
2021-02-16 3,500
2021-02-23 3,500
2021-03-02 3,500
2021-03-09 3,500Footnote*
2021-03-16 3,500
2021-03-23Footnote* 3,500
2021-03-29 3,500
2021-04-06 3,500Footnote*
2021-04-12 3,500Footnote*
2021-04-19 3,500Footnote*
2021-04-26 3,500Footnote*
2021-05-03 3,500Footnote*
2021-05-10 3,500Footnote*
2021-05-17 3,500Footnote*
2021-05-24 3,500Footnote*
2021-05-31 3,500Footnote*
2021-06-30 3,500Footnote*
2021-07-31 3,500Footnote*
2021-08-31 4,000
2021-09-30 4,000
Saskatchewan: Target 4,000
COVID-19 testing capacity for Saskatchewan (Target 4,000)
Date Projected daily maximum testing capacity
2020-09-03 1,800
2020-09-10 1,800
2020-09-17 1,800
2020-09-24 1,800
2020-10-01 1,800
2020-10-08 1,800
2020-10-15 1,800
2020-10-22 1,800
2020-10-29 1,800
2020-11-03 1,800
2020-11-10 2,100
2020-11-17 2,700
2020-11-24 2,700
2020-12-01 3,330
2020-12-08 3,450
2020-12-15 3,450
2020-12-22 3,450
2020-12-29 3,450
2021-01-05 3,846
2021-01-12 3,846
2021-01-19 3,846
2021-01-26 3,846
2021-02-02 3,846
2021-02-09 3,846Footnote*
2021-02-16 3,846Footnote*
2021-02-23 3,846
2021-03-02 3,846
2021-03-09 3,846
2021-03-16 4,000
2021-03-23 4,500
2021-03-29 4,500
2021-04-06 4,500
2021-04-12 4,500
2021-04-19 4,500
2021-04-26 4,500
2021-05-03 4,500
2021-05-10 4,500
2021-05-17 4,500
2021-05-24 4,500
2021-05-31 4,500
2021-07-31 4,500
2021-08-31 4,500
2021-09-30 3,000
Alberta: Target 22,000
COVID-19 testing capacity for Alberta (Target 22,000)
Date Projected daily maximum testing capacity
2020-09-03 12,000
2020-09-10 12,000
2020-09-17 12,000
2020-09-24 12,000
2020-10-01 15,500
2020-10-08 22,000
2020-10-15 22,000
2020-10-22 22,000
2020-10-29 22,000
2020-11-03 22,000
2020-11-10 22,000
2020-11-17 22,000
2020-11-24 22,000
2020-12-01 22,000
2020-12-08 22,000Footnote*
2020-12-15 22,000
2020-12-22 22,000
2020-12-29 22,000
2021-01-05 22,000
2021-01-12 22,000
2021-01-19 22,000
2021-01-26 22,000
2021-02-02 22,000
2021-02-09 22,000
2021-02-16 22,000
2021-02-23 22,000
2021-03-02 22,000
2021-03-09 22,000
2021-03-16 22,000
2021-03-23 22,000
2021-03-29 22,000
2021-04-06 22,000
2021-04-12 22,000
2021-04-19 22,000
2021-04-26 22,000
2021-05-03 22,000
2021-05-10 22,000
2021-05-17 22,000
2021-05-24 22,000
2021-05-31 22,000
2021-06-30 22,000
2021-07-31 22,000
2021-08-31 22,000
2021-09-30 22,000
British Columbia: Target 20,000
COVID-19 testing capacity for British Columbia (Target 20,000)
Date Projected daily maximum testing capacity
2020-09-03 7,842
2020-09-10 8,581
2020-09-17 7,996
2020-09-24 9,633
2020-10-01 9,714
2020-10-08 10,506
2020-10-15 10,586
2020-10-22 12,840
2020-10-29 13,685
2020-11-03 17,033
2020-11-10 17,333
2020-11-17 18,733
2020-11-24 18,733
2020-12-01 18,733
2020-12-08 18,945
2020-12-15 18,945
2020-12-22 18,945
2020-12-29 18,945
2021-01-05 19,439
2021-01-12 19,439
2021-01-19 19,817
2021-01-26 19,817
2021-02-02 19,817
2021-02-09 19,817
2021-02-16 19,817
2021-02-23 20,617
2021-03-02 20,617
2021-03-09 20,617
2021-03-16 20,617
2021-03-23 21,332
2021-03-29 21,332
2021-04-06 19,932
2021-04-12 18,932
2021-04-19 20,132
2021-04-26 20,132
2021-05-03 20,132
2021-05-10 20,132
2021-05-17 20,132
2021-05-24 20,132
2021-05-31 20,132
2021-06-30 20,132
2021-07-31 20,132
2021-08-31 20,132
2021-09-30 19,628
Yukon: Target 160
COVID-19 testing capacity for Yukon (Target 160)
Date Projected daily maximum testing capacity
2020-09-03 n/a
2020-09-10 n/a
2020-09-17 n/a
2020-09-24 n/a
2020-10-01 150
2020-10-08 150
2020-10-15 150
2020-10-22 150
2020-10-29 150
2020-11-03 150
2020-11-10 150
2020-11-17 150
2020-11-24 150
2020-12-01 150Footnote*
2020-12-08 150Footnote*
2020-12-15 150
2020-12-22 150
2020-12-22 150
2020-12-29 150
2021-01-05 150
2021-01-12 150
2021-01-19 150
2021-01-26 150Footnote*
2021-02-02 150Footnote*
2021-02-09 150
2021-02-16 150Footnote*
2021-02-23 150Footnote*
2021-03-02 150
2021-03-09 150Footnote*
2021-03-16 150Footnote*
2021-03-23 150
2021-03-29 150
2021-04-06 150
2021-04-12 150
2021-04-19 150
2021-04-26 150
2021-05-03 150
2021-05-10 150
2021-05-17 150
2021-05-24 150
2021-05-31 150
2021-06-30 150
2021-07-31 150
2021-08-31 150
2021-09-30 150
Northwest Territories: Target 225
COVID-19 testing capacity for Northwest Territories (Target 225)
Date Projected daily maximum testing capacity
2020-09-03 n/a
2020-09-10 n/a
2020-09-17 n/a
2020-09-24 n/a
2020-10-01 48
2020-10-08 48
2020-10-15 48
2020-10-22 48
2020-10-29 75
2020-11-03 75
2020-11-10 75
2020-11-17 75
2020-11-24 75
2020-12-01 75Footnote*
2020-12-08 75Footnote*
2020-12-15 75Footnote*
2020-12-22 75
2020-12-29 75
2021-01-05 75
2021-01-12 75
2021-01-19 75
2021-01-26 75*
2021-02-02 110
2021-02-09 110
2021-02-16 110
2021-02-23 110
2021-03-02 110
2021-03-09 110
2021-03-16 110
2021-03-23 110
2021-03-29 110
2021-04-06 110
2021-04-12 100
2021-04-19 110
2021-04-26 110
2021-05-03 110
2021-05-10 110
2021-05-17 110
2021-05-24 110
2021-05-31 110
2021-06-30 110
2021-07-31 110
2021-08-31 110
2021-09-30 110
Nunavut: Target n/a
COVID-19 testing capacity for Nunavut (Target n/a)
Date Projected daily maximum testing capacity
2020-09-03 n/a
2020-09-10 n/a
2020-09-17 n/a
2020-09-24 n/a
2020-10-01 n/a
2020-10-08 n/a
2020-10-15 80
2020-10-22 80
2020-10-29 80
2020-11-03 100
2020-11-10 200
2020-11-17 200
2020-11-24 200
2020-12-01 200
2020-12-08 200
2020-12-15 250
2020-12-22 250
2020-12-29 250
2021-01-05 250
2021-01-12 250
2021-01-19 300
2021-01-26 300
2021-02-02 300
2021-02-09 300
2021-02-16 300
2021-02-23 300
2021-03-02 300
2021-03-09 300
2021-03-16 300
2021-03-23 300
2021-03-29 300
2021-04-06 300
2021-04-12 300
2021-04-19 300
2021-04-26 300
2021-05-03 300
2021-05-10 300
2021-05-17 300
2021-05-24 300
2021-05-31 300
2021-06-30 300
2021-07-31 300
2021-08-31 300
2021-09-30 300
Canada: Target 170,720 - 171,220
COVID-19 testing capacity for Canada (Target 170,720 - 171,220)
Date Projected daily maximum testing capacity
2020-09-03 84,550
2020-09-10 89,951
2020-09-17 92,030
2020-09-24 94,049
2020-10-01 82,504
2020-10-08 113,046
2020-10-15 113,911
2020-10-22 128,838
2020-10-29 132,234
2020-11-03 141,072
2020-11-10 149,172
2020-11-17 153,064
2020-11-24 154,838
2020-12-01 155,309
2020-12-08 163,218
2020-12-15 169,036
2020-12-22 171,399
2020-12-29 172,997
2021-01-05 174,103
2021-01-12 215,545
2021-01-19 213,775
2021-01-26 216,930
2021-02-02 213,350
2021-02-09 216,159
2021-02-16 213,270
2021-02-23 218,560
2021-03-02 215,959
2021-03-09 219,131
2021-03-16 219,599
2021-03-23 222,124
2021-03-29 222,779
2021-04-06 225,534
2021-04-12 226,763
2021-04-19 227,701
2021-04-26 227,401
2021-05-03 235,213
2021-05-10 240,040
2021-05-17 240,413
2021-05-24 238,046
2021-05-31 238,280
2021-06-30 237,990
2021-07-31 237,990
2021-08-31 240,095
2021-09-30 238,091

Related links

Report a problem or mistake on this page
Please select all that apply:

Thank you for your help!

You will not receive a reply. For enquiries, contact us.

Date modified: